Supercharge Your Innovation With Domain-Expert AI Agents!

A kind of trail dual-target mutant protein mur6s4tr, its preparation method and application

A mutant protein, dual-target technology, applied in the TRAIL dual-target mutant protein MuR6S4TR, the preparation of a new generation of high-efficiency tumor cell apoptosis-inducing drugs, can solve problems such as non-pharmacological implementation, and achieve significant amplification potential and anti-tumor The effect of improving the activity and reducing the purification cost

Active Publication Date: 2021-07-02
南京华创生物技术有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the development process of small-molecule Smac agonist drugs, subject to the safety of small-molecule drugs, the difference between the two types of drugs and TRAIL, the convenience of single use, the stability of clinical efficacy and other factors, it is not an optimal The best way to achieve pharmaceuticals

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of trail dual-target mutant protein mur6s4tr, its preparation method and application
  • A kind of trail dual-target mutant protein mur6s4tr, its preparation method and application
  • A kind of trail dual-target mutant protein mur6s4tr, its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Sequence and primer design of TRAIL dual-target mutein

[0073]On the basis of the sequence of TRAIL-penetrating peptide-like mutant TRAIL-MuR6 (PCT / CN2015 / 073524: TRAIL-penetrating peptide-like mutant MuR6, preparation method and application), the present invention selectively converts the second to The 8-11 amino acid sequence after the 7-position RRRRRR (R6) is mutated from glutamine, arginine, valine, alanine (QRVA) to the N-terminal 4 peptide of Smac protein, namely alanine, valine Acid, proline, isoleucine (AVPI) sequence, with 4 mutation sites, making the N-terminal of the mutant protein become 6 consecutive arginines (RRRRRR) followed by the N-terminal 4-peptide alanine of the Smac protein Acid, valine, proline, isoleucine (AVPI) coding sequence. The new mutant protein has both the properties of a penetrating peptide-like mutant and the activity of a second mitochondria-derived activator of caspase. We named the new mutant protein TRAIL dual-target mutant prot...

Embodiment 2

[0085] The MuR6S4TR gene fragment was amplified by two-step PCR, and the fragment was directly ligated with the expression vector pET32a cut with the same restriction enzyme after double enzyme digestion, and a single colony of the ligation product was picked and identified.

[0086] See Example 1 for primer design, and the pET32a / MuR6TR template comes from patent PCT / CN2015 / 073524.

[0087] Specifically, the pET32a / MuR6TR cDNA sequence is shown in SEQ ID No:3.

[0088] Experimental procedure

[0089] 1. PCR amplification of the target fragment of MuR6S4TR

[0090] 1. Use the MuR6S4TR-2 / TR-Eco-R primer pair to amplify the MuR6S4TR-1 target fragment, prepare a reaction system according to Table 1, and the reaction system is 50 μl.

[0091] 2. Vortex to mix, centrifuge briefly, and collect the solution at the bottom of the tube.

[0092] 3. See Table 2 for the PCR amplification reaction conditions.

[0093] 4. Electrophoresis and photography.

[0094] 5. The target fragment...

Embodiment 3

[0159] Expression test of plasmid pET32a-MuR6S4TR

[0160] The plasmid with correct sequencing obtained in Example 2 was transformed into competent Escherichia coli BL21(DE3), and a single bacterium was picked for expression test to investigate the expression effect.

[0161] Experimental procedure

[0162] 1. Plasmid transformation and strain preservation

[0163] 1. Prepare 100ml of LB medium and sterilize at 121°C for 20min.

[0164] 2. Take 1 μl of pET32a-MuR6S4TR plasmid and add it to 100 μl BL21(DE3) competent cells, and put it in ice bath for 30 minutes.

[0165] 3. Heat shock in a water bath at 42°C for 90 seconds.

[0166] 4. Incubate on ice for 3 minutes.

[0167] 5. Take 20 μl of transformed competent cells and smear them all on LB solid medium containing Amp, and culture overnight at 37°C.

[0168] 6. After colonies grow on the plate the next day, pick two single bacteria on the plate and add 50ml LB (Amp + ) at 37°C overnight.

[0169] 7. Preserve 20 glycer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of genetic engineering drugs and provides a TRAIL mutant protein MuR6S4TR, its preparation method and application. The 2-11th position of the N-terminal amino acid sequence of the mutant protein is composed of the membrane-penetrating peptide sequence RRRRR (R6) and the binding sequence AVPI of the apoptosis inhibitor XIAP, and the 12-169th position is the TRAIL protein peptide (124-281aa), specifically The sequence is shown in SEQ ID NO:2.

Description

technical field [0001] The present invention relates to the field of genetic engineering drugs, in particular to a TRAIL dual-target mutant protein MuR6S4TR, its preparation method and application. The TRAIL dual-target mutant protein MuR6S4TR in the present invention has superior therapeutic effects on various types of tumors, and is A new generation of highly effective drug for inducing tumor cell apoptosis with great potential. Background technique [0002] 1. The progress and significance of Apo 2L / TRAIL in tumor therapy [0003] Tumor necrosis factor-related apoptosis-inducing ligand (Tumor necrosis factor-related apoptosis-inducing ligand, TRAIL) is a member of the tumor necrosis factor (Tumor necrosis factor, TNF) superfamily. In 1996, it was independently cloned by Pitti et al., who named it apoptin 2 ligand (Apo 2Ligand, Apo 2L). Later studies confirmed that Apo 2L and TRAIL are essentially the same protein, so it can be customarily called Apo 2L / TRAIL. The funct...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C07K14/525C12N15/28C12N15/70A61K38/17A61P35/00
CPCA61K38/17C07K14/525C07K19/00C12N15/70A61P35/00A61K38/00C07K14/70575
Inventor 陈守春徐琦闫娟黄先洲魏利佳胡海洋
Owner 南京华创生物技术有限公司
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com